Senses Disorder TRIZ Cases
- Trophic Composition for Corneal Epithelium Regeneration
A trophic composition with a complex nutritive base and collagenase inhibitor promotes corneal epithelial cell viability.
- TACI-Immunoglobulin Fusion Protein Formulation Stability
Acetate buffers at pH 4.5-5.5 prevent aggregation of TACI-immunoglobulin fusion proteins during storage.
- Aceclidine Eye Drops for Presbyopia
Aceclidine eye drops activate M1 receptors to constrict the pupil, improving near vision without ciliary muscle spasms.
- Novel Xanthine Oxidase Inhibitors for Safer Gout Treatment
Novel pyrazolo[3,4-b]pyridine compounds inhibit xanthine oxidase to reduce severe side effects from allopurinol.
- Imatinib Eye Drops for Dry Eye Corneal Damage
Imatinib eye drops inhibit tyrosine kinase activity to prevent corneal damage and inflammation in dry eye syndrome.
- Mesenchymal Stem Cell Exosomes Protect Cochlear Hair Cells
Exosomes from mesenchymal stem cells deliver HSP70 protein to shield auditory hair cells from ototoxic drug damage.
- Phase-Separated Multi-Block Copolymers for Protein Delivery
Phase-separated multi-block copolymers prevent protein aggregation and acidic micro-environments by creating hydrophilic pathways for sustained release.
- Pyridopyrazinone Derivatives Glucose-Dependent Insulin Secretion
Pyridopyrazinone derivatives restore glucose-responsive insulin release, preventing hyperinsulinemia and beta cell exhaustion in type 2 diabetes treatment.
- Dynamic VEGF Antagonist Dosing Regimen for Angiogenic Eye Disorders
A dynamic dosing regimen using VEGF antagonists adjusts treatment intervals to maintain therapeutic efficacy.
- Amarogentin Bitter Taste Receptor Agonists for Skin Barrier Repair
Topical amarogentin activates bitter taste receptors to reduce inflammation and strengthen skin barrier function.
- Guide RNA Targeting Mutant IMPDH1 Allele for Retinitis Pigmentosa
Guide RNA targets single nucleotide polymorphism in mutant allele to enable precise CRISPR-mediated mRNA degradation.
- Peptide-Based Proteasome Inhibitors for Selective Senescent Cell Elimination
Peptide-based proteasome inhibitors with C-terminal electrophilic groups inactivate target enzymes via covalent bonding.
- NO-Independent sGC Stimulators for Pulmonary Hypertension
Formula I compounds bypass reduced nitric oxide bioavailability by directly activating heme-dependent soluble guanylate cyclase to treat pulmonary hypertension.
- Selective Bcl-2 Inhibitors for Autoimmune Disease Treatment
Selective Bcl-2 inhibitors minimize off-target effects on Bcl-xL while treating systemic lupus erythematosus, lupus nephritis, and Sjogren's Syndrome.